行情

KMPH

KMPH

KemPharm
NASDAQ

实时行情|Nasdaq Last Sale

0.8150
-0.0111
-1.34%
休市 16:00 09/20 EDT
开盘
0.8125
昨收
0.8261
最高
0.8200
最低
0.7900
成交量
17.21万
成交额
--
52周最高
5.00
52周最低
0.7100
市值
2,425.32万
市盈率(TTM)
-0.4225
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

KMPH 新闻

  • 欧洲最大骗税案开审 "掠夺欧洲的男人"出庭披露内幕
  • 新京报.1小时前
  • 2025年或推出AR眼镜 Facebook能否扭转行业颓势?
  • 新浪财经-自媒体综合.2小时前
  • 据悉任天堂千方百计将Switch Lite售价压低至200美元
  • 新浪财经综合.3小时前
  • 猪瘟扩散 日本政府决定为生猪接种疫苗
  • 央视.4小时前

更多

所属板块

生物技术和医学研究
+0.62%
制药与医学研究
+0.95%

热门股票

名称
价格
涨跌幅

KMPH 简况

KemPharm, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company's product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP). The Company is developing KP201/APAP as an immediate release (IR), a product candidate for the short-term, or no longer than 14 days for the management of acute pain. The Company has designed KP201/APAP with abuse-deterrent properties to address the epidemic of opioid abuse in the United States. The Company also focuses on developing the pipeline of additional prodrug product candidates that targets pain and attention deficit hyperactivity disorder (ADHD). The Company's products include KP201/IR (APAP-free), KP511/ER, KP415, KP606/IR and KP746.
展开

Webull提供KemPharm Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。